TS03 Inc Trust Units TSTIF

RE:RE:RE:Investment Relations need to step up their game

[echo2]

As this has just been accepted for publication, it will likely not be in print until the Fall, possibibly mid-late October. "The paper describes the first and only gravity based direct inoculation (intentional bacterial contamination) method which meets the requirements of US regulators for confirmation that the inoculum is deposited into the middle of each channel of complex multichannel endoscopes.  Additionally, the paper describes the TSO3 STERIZONE® low temperature sterilization system and its ability to sterilize such scopes." 

The important point is that it is accepted and that we know the paper will further validate the testing protocols, including "in use" clinical testing, that TSO3 is using in MB and that the FDA regards these new testing protocols unique to TSO3 that innoculate and test for contamination deep into the mid-areas of the complex lumen scopes as valid. 

 

The actual publication will be a formality, though it will likely get a bit of industry and press attention at the time it comes out as more and more people become aware of the VP4's unique industry leading and revolutionary capabilities including TSO3's new validation methods.

The annual meeting and first quarter announcement should be out in the next week with a date in the first week of May, such as Wednesday May 3, given past administrative practices.